Irinotecan and Anlotinib for Epithelioid Sarcoma

Peking University

Status: Withdrawn

Conditions: Objective Response; Overall Survival

Treatments: Drug: VIA combination treatment

Study type: Interventional

Funder types: Other

Identifiers

NCT05656222

PKUPH-sarcoma 15

Details and patient eligibility

About

Epithelioid sarcoma is a rare soft tissue sarcoma characterized by SMARCB1/INI1 deficiency. Much attention has been paid to the selective EZH2 inhibitor tazemetostat, where other systemic treatments are generally ignored. To explore alternative treatment options, we studied the effects of irinotecan-based chemotherapy in a series of epithelioid sarcoma patients.

Sex: All

Ages: 3+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• (1) Grade 2 or 3 ES confirmed histologically using the American Joint Committee on Cancer (AJCC) system ;
• (2) patients presented with measurable lesions using the Response Evaluation Criteria In Solid Tumors (RECIST1.1) and were not amenable to surgical resection or radiotherapy;
• (3) primary or secondary metastatic disease;
• (4) received more than two courses of the VIA regimen;
• (5) no concurrent treatment was given while on the VIA regimen;
• (6) follow-up information and evaluation after chemotherapy were available.

Exclusion criteria

• less than 4 cycles of treatment;
• medical records were not complete.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

VIA treatment Group

Experimental group

Treatment:

Drug: VIA combination treatment